Omeros SG&A Expenses 2010-2024 | OMER
Omeros sg&a expenses from 2010 to 2024. Sg&a expenses can be defined as the sum of all selling, general and administrative expenses.
| Omeros Annual SG&A Expenses (Millions of US $) |
|
|---|---|
| 2024 | $50 |
| 2023 | $50 |
| 2022 | $51 |
| 2021 | $55 |
| 2020 | $49 |
| 2019 | $40 |
| 2018 | $52 |
| 2017 | $52 |
| 2016 | $44 |
| 2015 | $35 |
| 2014 | $23 |
| 2013 | $16 |
| 2012 | $11 |
| 2011 | $8 |
| 2010 | $9 |
| 2009 | $5 |
| Omeros Quarterly SG&A Expenses (Millions of US $) |
|
|---|---|
| 2024-12-31 | $12 |
| 2024-09-30 | $11 |
| 2024-06-30 | $14 |
| 2024-03-31 | $12 |
| 2023-12-31 | $11 |
| 2023-09-30 | $16 |
| 2023-06-30 | $11 |
| 2023-03-31 | $11 |
| 2022-12-31 | $14 |
| 2022-09-30 | $12 |
| 2022-06-30 | $14 |
| 2022-03-31 | $11 |
| 2021-12-31 | $13 |
| 2021-09-30 | $14 |
| 2021-06-30 | $15 |
| 2021-03-31 | $13 |
| 2020-12-31 | $-5 |
| 2020-09-30 | $20 |
| 2020-06-30 | $17 |
| 2020-03-31 | $18 |
| 2019-12-31 | $-9 |
| 2019-09-30 | $17 |
| 2019-06-30 | $17 |
| 2019-03-31 | $15 |
| 2018-12-31 | $15 |
| 2018-09-30 | $13 |
| 2018-06-30 | $13 |
| 2018-03-31 | $11 |
| 2017-12-31 | $12 |
| 2017-09-30 | $12 |
| 2017-06-30 | $16 |
| 2017-03-31 | $12 |
| 2016-12-31 | $12 |
| 2016-09-30 | $10 |
| 2016-06-30 | $10 |
| 2016-03-31 | $11 |
| 2015-12-31 | $9 |
| 2015-09-30 | $9 |
| 2015-06-30 | $8 |
| 2015-03-31 | $9 |
| 2014-12-31 | $8 |
| 2014-09-30 | $6 |
| 2014-06-30 | $5 |
| 2014-03-31 | $4 |
| 2013-12-31 | $4 |
| 2013-09-30 | $4 |
| 2013-06-30 | $4 |
| 2013-03-31 | $4 |
| 2012-12-31 | $4 |
| 2012-09-30 | $3 |
| 2012-06-30 | $2 |
| 2012-03-31 | $2 |
| 2011-12-31 | $2 |
| 2011-09-30 | $2 |
| 2011-06-30 | $2 |
| 2011-03-31 | $2 |
| 2010-12-31 | $3 |
| 2010-09-30 | $2 |
| 2010-06-30 | $2 |
| 2010-03-31 | $2 |
| 2009-12-31 | $1 |
| 2009-09-30 | $1 |
| 2009-06-30 | $1 |
| 2009-03-31 | $1 |
| Sector | Industry | Market Cap | Revenue |
|---|---|---|---|
| Medical | Medical Products Manufacturing | $0.397B | $0.000B |
| Omeros Corporation is a clinical-stage biopharmaceutical company committed to discovering, developing and commercializing products focused on inflammation and disorders of the central nervous system. Omeros' most clinically advanced product candidates are derived from its proprietary PharmacoSurgery(TM) platform designed to improve clinical outcomes of patients undergoing arthroscopic, ophthalmological, urological and other surgical and medical procedures. Omeros has four ongoing PharmacoSurgery(TM) clinical development programs, and its lead product candidate, OMS103HP, is being evaluated in Phase 3 clinical trials for use during arthroscopic surgery to improve postoperative joint function and reduce postoperative pain. Omeros is also building a diverse pipeline of preclinical programs targeting inflammation and central nervous system disorders. | |||
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Abbott Laboratories (ABT) | United States | $230.702B | 27.74 |
| Boston Scientific (BSX) | United States | $154.217B | 38.61 |
| Stryker (SYK) | United States | $145.561B | 30.44 |
| EssilorLuxottica (ESLOY) | France | $133.244B | 0.00 |
| Medtronic (MDT) | Ireland | $107.028B | 15.63 |
| Lonza Group Ag (LZAGY) | Switzerland | $52.631B | 0.00 |
| Haleon (HLN) | United Kingdom | $47.943B | 27.26 |
| ResMed (RMD) | United States | $35.287B | 26.50 |
| GE HealthCare Technologies (GEHC) | United States | $31.763B | 15.08 |
| Agilent Technologies (A) | United States | $30.897B | 20.41 |
| Terumo (TRUMY) | Japan | $29.152B | 0.00 |
| Koninklijke Philips (PHG) | Netherlands | $24.100B | 17.21 |
| Insulet (PODD) | United States | $18.209B | 77.71 |
| Zimmer Biomet Holdings (ZBH) | United States | $17.901B | 11.50 |
| Baxter (BAX) | United States | $15.608B | 11.66 |
| Smith & Nephew SNATS (SNN) | United Kingdom | $12.425B | 0.00 |
| Sunny Optical Technology (SNPTF) | China | $9.032B | 0.00 |
| Demant (WILYY) | Denmark | $7.970B | 0.00 |
| Lantheus Holdings (LNTH) | United States | $7.395B | 18.18 |
| Bio-Rad Laboratories (BIO) | United States | $6.728B | 22.75 |
| Prestige Consumer Healthcare (PBH) | United States | $4.111B | 19.62 |
| Shandong Weigao Medical Polymer (SHWGF) | China | $3.459B | 0.00 |
| Perrigo (PRGO) | Ireland | $3.444B | 9.86 |
| ICU Medical (ICUI) | United States | $3.347B | 28.51 |
| Haemonetics (HAE) | United States | $3.139B | 14.77 |
| Envista Holdings (NVST) | United States | $2.876B | 23.90 |
| GN Store Nord (GNNDY) | Denmark | $2.071B | 17.15 |
| QuidelOrtho (QDEL) | United States | $1.868B | 15.64 |
| LeMaitre Vascular (LMAT) | United States | $1.817B | 40.63 |
| AtriCure (ATRC) | United States | $1.439B | 0.00 |
| Green Thumb Industries (GTBIF) | United States | $1.359B | 21.40 |
| Neogen (NEOG) | United States | $1.224B | 15.67 |
| AdaptHealth (AHCO) | United States | $1.173B | 11.30 |
| Kestra Medical Technologies (KMTS) | United States | $1.159B | 0.00 |
| BioLife Solutions (BLFS) | United States | $1.150B | 0.00 |
| InMode (INMD) | Israel | $0.991B | 9.08 |
| Phibro Animal Health (PAHC) | United States | $0.791B | 12.13 |
| Evolus (EOLS) | United States | $0.774B | 0.00 |
| Owens & Minor (OMI) | United States | $0.632B | 5.38 |
| Curaleaf Holdings (CURLF) | Canada | $0.618B | 0.00 |
| CeriBell (CBLL) | United States | $0.583B | 0.00 |
| Valneva SE (VALN) | France | $0.557B | 0.00 |
| Maravai LifeSciences Holdings (MRVI) | United States | $0.539B | 0.00 |
| Capricor Therapeutics (CAPR) | United States | $0.470B | 0.00 |
| Tilray Brands (TLRY) | Canada | $0.442B | 0.00 |
| Cresco Labs (CRLBF) | United States | $0.437B | 0.00 |
| Surmodics (SRDX) | United States | $0.386B | 0.00 |
| SNDL (SNDL) | Canada | $0.355B | 0.00 |
| VAREX IMAGING (VREX) | United States | $0.348B | 15.09 |
| SEMPERIT AG HLD (SEIGY) | Austria | $0.317B | 0.00 |
| Verano Holdings (VRNOF) | United States | $0.312B | 0.00 |
| Viemed Healthcare (VMD) | United States | $0.290B | 26.18 |
| Sanara MedTech (SMTI) | United States | $0.288B | 0.00 |
| Aurora Cannabis (ACB) | Canada | $0.265B | 47.20 |
| Sanuwave Health (SNWV) | United States | $0.265B | 0.00 |
| Cerus (CERS) | United States | $0.249B | 0.00 |
| ZimVie (ZIMV) | United States | $0.247B | 14.80 |
| Canopy Growth (CGC) | Canada | $0.234B | 0.00 |
| Quanterix (QTRX) | United States | $0.225B | 0.00 |
| OraSure Technologies (OSUR) | United States | $0.221B | 0.00 |
| High Tide (HITI) | Canada | $0.192B | 0.00 |
| Biote (BTMD) | United States | $0.178B | 4.06 |
| Utah Medical Products (UTMD) | United States | $0.172B | 13.83 |
| TriSalus Life Sciences (TLSI) | United States | $0.165B | 0.00 |
| Brainsway (BWAY) | Israel | $0.164B | 51.24 |
| Organigram Global (OGI) | Canada | $0.149B | 0.00 |
| FitLife Brands (FTLF) | United States | $0.145B | 17.91 |
| Jin Medical (ZJYL) | China | $0.125B | 0.00 |
| TerrAscend (TSNDF) | Canada | $0.118B | 0.00 |
| Exagen (XGN) | United States | $0.113B | 0.00 |
| Agape ATP (ATPC) | $0.105B | 0.00 | |
| MacroGenics (MGNX) | United States | $0.103B | 0.00 |
| Oramed Pharmaceuticals (ORMP) | United States | $0.094B | 0.00 |
| Quipt Home Medical (QIPT) | United States | $0.093B | 0.00 |
| Jushi Holdings (JUSHF) | United States | $0.081B | 0.00 |
| Fonar (FONR) | United States | $0.076B | 10.61 |
| Veru (VERU) | United States | $0.075B | 0.00 |
| InterCure (INCR) | Israel | $0.072B | 0.00 |
| Zynex (ZYXI) | United States | $0.064B | 0.00 |
| Cytosorbents (CTSO) | United States | $0.057B | 0.00 |
| United Health Products (UEEC) | United States | $0.057B | 0.00 |
| ImmuCell (ICCC) | United States | $0.047B | 0.00 |
| Apyx Medical (APYX) | United States | $0.044B | 0.00 |
| Modular Medical (MODD) | United States | $0.041B | 0.00 |
| Rockwell Medical (RMTI) | United States | $0.041B | 59.50 |
| Safety Shot (SHOT) | United States | $0.038B | 0.00 |
| United-Guardian (UG) | United States | $0.037B | 11.31 |
| Nephros (NEPH) | United States | $0.020B | 0.00 |
| INLIF (INLF) | $0.017B | 0.00 | |
| Trinity Biotech (TRIB) | Ireland | $0.015B | 0.00 |
| Cellectar Biosciences (CLRB) | United States | $0.012B | 0.00 |
| Allurion Technologies (ALUR) | United States | $0.011B | 0.00 |
| Flora Growth (FLGC) | United States | $0.011B | 0.00 |
| Meihua Medical Technologies (MHUA) | China | $0.007B | 0.00 |
| GlucoTrack (GCTK) | United States | $0.005B | 0.00 |
| Innovative Eyewear (LUCY) | United States | $0.005B | 0.00 |
| Senestech (SNES) | United States | $0.004B | 0.00 |
| IM Cannabis (IMCC) | Canada | $0.004B | 0.00 |
| Akanda (AKAN) | United Kingdom | $0.002B | 0.00 |
| Sharps Technology (STSS) | United States | $0.000B | 0.00 |
| InVivo Therapeutics Holdings (NVIVQ) | United States | $0.000B | 0.00 |